LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Capricor Therapeutics Inc

Închisă

14.2 7.9

Rezumat

Modificarea prețului

24h

Curent

Minim

13.35

Maxim

14.33

Indicatori cheie

By Trading Economics

Venit

-17M

-24M

EPS

-0.53

Marjă de profit

-63.938

Angajați

160

EBITDA

-17M

-25M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+212.59% upside

Dividende

By Dow Jones

Următoarele câștiguri

6 aug. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

142M

467M

Deschiderea anterioară

6.3

Închiderea anterioară

14.2

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

Capricor Therapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

4 mar. 2025, 15:41 UTC

Principalele dinamici ale pieței

Capricor Therapeutics Shares Rise on FDA Priority Review

Comparație

Modificare preț

Capricor Therapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

212.59% sus

Prognoză pe 12 luni

Medie 41.2 USD  212.59%

Maxim 77 USD

Minim 25 USD

În baza a 6 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruCapricor Therapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

6 ratings

6

Cumpărare

0

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

6.79 / 7.59Suport & Rezistență

Termen scurt

Very Strong Bearish Evidence

Termen mediu

Strong Bearish Evidence

Termen lung

Neutral Evidence

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Capricor Therapeutics Inc

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment of duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs. The company's lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase 3 clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD). It also focused on developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases. In addition, the company develops CAP-2003, under pre-clinical development for the treatment of trauma related injuries and conditions. It has collaboration and distribution agreement with Nippon Shinyaku Co. Ltd., collaboration agreement with National Institute of Allergy and Infectious Diseases, license agreements with the Johns Hopkins University and Cedars-Sinai Medical Center, as well as cell line license agreement with Life Technologies Corporation. The company was founded in 2005 and is headquartered in San Diego, California.